Skip to main content
Journal cover image

Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.

Publication ,  Journal Article
Kharasch, ED; Hoffer, C; Whittington, D; Sheffels, P
Published in: Clin Pharmacol Ther
December 2003

INTRODUCTION: There is considerable and unexplained individual variability in the morphine dose-effect relationship. The efflux pump P-glycoprotein regulates brain access and intestinal absorption of numerous drugs. Morphine is a P-glycoprotein substrate in vitro, and P-glycoprotein affects morphine brain access and pharmacodynamics in animals. However, the role of P-glycoprotein in human morphine disposition and clinical effects is unknown. This investigation tested the hypothesis that plasma concentrations and clinical effects of oral and intravenous morphine are greater after inhibition of intestinal and brain P-glycoprotein, with the P-glycoprotein inhibitor quinidine used as an in vivo probe. METHODS: Two randomized, double-blind, placebo-controlled, balanced crossover studies were conducted in normal healthy volunteers after institutional review board-approved informed consent was obtained. In the first protocol, pupil diameter was evaluated after intravenous morphine administration (0.15 mg/kg), 1 hour after oral quinidine or placebo. In the second protocol, plasma morphine and glucuronide metabolite concentrations and pupil diameters were evaluated after oral morphine administration (30 mg), dosed 1 hour after oral quinidine (600 mg) or placebo. RESULTS: Quinidine had no effect on intravenous morphine effects (time to maximum miosis, maximum effect, or area under the curve [AUC] of miosis versus time). Quinidine increased the oral morphine maximum plasma concentration (31.8 +/- 14.9 ng/mL versus 16.9 +/- 7.4 ng/mL, P <.05) and AUC (65.1 +/- 21.5 versus 40.8 ng. h. mL(-1) +/- 14 ng. h. mL(-1), P <.05) but had no effect on elimination rate. Plasma morphine glucuronide concentrations were unchanged; however, the morphine glucuronide/morphine ratios were diminished by quinidine. Differences in oral morphine miosis (AUC, 16.8 +/- 9.3 mm. h versus 10.8 +/- 6.5 mm. h; P <.05) were commensurate with changes in plasma morphine concentration, and concentration-effect relationships were unchanged. Quinidine altered subjective self-assessments of oral but not intravenous morphine effects. DISCUSSION: Quinidine increased the absorption and plasma concentrations of oral morphine, suggesting that intestinal P-glycoprotein affected the absorption, bioavailability, and, hence, clinical effects of oral morphine. However, quinidine had no effect on morphine concentration-effect relationships, suggesting that if quinidine is an effective inhibitor of brain P-glycoprotein then P-glycoprotein did not appear to have a significant effect on brain access of morphine.

Duke Scholars

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

December 2003

Volume

74

Issue

6

Start / End Page

543 / 554

Location

United States

Related Subject Headings

  • Quinidine
  • Pharmacology & Pharmacy
  • Morphine
  • Metabolic Clearance Rate
  • Male
  • Intestinal Absorption
  • Injections, Intravenous
  • Humans
  • Half-Life
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kharasch, E. D., Hoffer, C., Whittington, D., & Sheffels, P. (2003). Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther, 74(6), 543–554. https://doi.org/10.1016/j.clpt.2003.08.011
Kharasch, Evan D., Christine Hoffer, Dale Whittington, and Pam Sheffels. “Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.Clin Pharmacol Ther 74, no. 6 (December 2003): 543–54. https://doi.org/10.1016/j.clpt.2003.08.011.
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther. 2003 Dec;74(6):543–54.
Kharasch, Evan D., et al. “Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.Clin Pharmacol Ther, vol. 74, no. 6, Dec. 2003, pp. 543–54. Pubmed, doi:10.1016/j.clpt.2003.08.011.
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther. 2003 Dec;74(6):543–554.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

ISSN

0009-9236

Publication Date

December 2003

Volume

74

Issue

6

Start / End Page

543 / 554

Location

United States

Related Subject Headings

  • Quinidine
  • Pharmacology & Pharmacy
  • Morphine
  • Metabolic Clearance Rate
  • Male
  • Intestinal Absorption
  • Injections, Intravenous
  • Humans
  • Half-Life
  • Female